To systematically evaluate the clinical efficacy and safety of Pudilan Antiphlogistic Oral Liquid combined with Western medicine in the treatment of mycoplasma pneumonia(MPP) in children.Methods:A comprehensive search was conducted for randomized controlled trials(RCTs) on the use of Pudilan Antiphlogistic Oral Liquid combined with Western medicine for treating pediatric MPP.Data were extracted and analyzed using the statistical software RevMan 5.3.Results:A total of 13 studies involving 1 313 patients were included，with 661 patients in the observation group and 652 in the control group.The clinical efficacy of Pudilan Antiphlogistic Oral Liquid combined with Western medicine was higher than that of Western medicine alone(RR=1.17，95%CI 1.13 to 1.22，P<0.000 1).The combined treatment also showed better outcomes in terms of fever resolution time(MD=-1.29，95%CI -1.35 to -1.22，P<0.000 1)，lung rale resolution time on auscultation(MD=-1.77，95%CI -1.85 to -1.69，P<0.000 1)，and cough symptom resolution time(MD=-2.59，95%CI -2.67 to -2.52，P<0.000 1) compared to Western medicine alone.The GRADE evaluation indicated that the quality of evidence was generally low.Conclusion:Pudilan Antiphlogistic Oral Liquid combined with Western medicine is more effective than Western medicine alone in treating pediatric MPP，with fewer adverse reactions and better safety.